NASDAQ:CRTXCortexyme Stock Price, Forecast & News

Cortexyme's stock was trading at $37.02 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CRTX stock has increased by 27.6% and is now trading at $47.23. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cortexyme in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cortexyme.

Cortexyme is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Cortexyme.

Cortexyme, Inc. (NASDAQ:CRTX) announced its quarterly earnings data on Tuesday, May, 12th. The biopharmaceutical company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.45) by $0.16. View Cortexyme's earnings history.

3 equities research analysts have issued 1-year price targets for Cortexyme's shares. Their forecasts range from $59.00 to $76.00. On average, they expect Cortexyme's share price to reach $68.33 in the next year. This suggests a possible upside of 44.7% from the stock's current price. View analysts' price targets for Cortexyme.

Press coverage about CRTX stock has been trending negative on Friday, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cortexyme earned a news sentiment score of -2.3 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news about Cortexyme.

Cortexyme saw a drop in short interest during the month of June. As of June 30th, there was short interest totaling 1,510,000 shares, a drop of 13.2% from the June 15th total of 1,740,000 shares. Based on an average daily volume of 149,000 shares, the short-interest ratio is presently 10.1 days. Approximately 12.6% of the shares of the stock are sold short. View Cortexyme's Current Options Chain.

Some companies that are related to Cortexyme include Cerner (CERN), HMS (HMSY), Omnicell (OMCL), Allscripts Healthcare Solutions (MDRX), HealthStream (HSTM), Vocera Communications (VCRA) and Computer Programs & Systems (CPSI). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cortexyme investors own include Honeywell International (HON), AT&T (T), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Verizon Communications (VZ), Cisco Systems (CSCO), CVS Health (CVS), Thermo Fisher Scientific (TMO) and Home Depot (HD).

(CRTX) raised $75 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 4,400,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

Cortexyme trades on the NASDAQ under the ticker symbol "CRTX."

Shares of CRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CRTX stock can currently be purchased for approximately $47.23.

Cortexyme has a market capitalization of $1.39 billion. The biopharmaceutical company earns $-36,980,000.00 in net income (profit) each year or ($1.94) on an earnings per share basis. Cortexyme employs 16 workers across the globe.

The official website for Cortexyme is www.cortexyme.com.

Cortexyme's mailing address is 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 415-910-5717 or via email at [email protected]